BiotechTube
Scarab Genomics

Scarab Genomics

Madison, United States· Est.
scarabgenomics.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $1.7M

Overview

Scarab Genomics leverages synthetic biology to create optimized bacterial production platforms and essential biopharmaceutical components. Its flagship technology is the Clean Genome® E. coli, a reduced-genome strain offering enhanced genetic stability and metabolic efficiency for producing proteins and plasmid DNA. The company generates revenue through product sales of strains, vectors, and carrier proteins (CRM197, Protein D), as well as through licensing agreements and partnerships, positioning it as a key enabler for vaccine developers and biomanufacturers.

Infectious Disease

Technology Platform

Clean Genome® E. coli strains (reduced-genome hosts for enhanced stability and yield) and C-Flow™ continuous fermentation system for biopharmaceutical production.

Funding History

2
Total raised:$1.7M
Seed$1.2M
Grant$500K

Opportunities

The booming markets for conjugate vaccines, gene therapies, and mRNA technologies create strong demand for efficient, scalable production systems and key raw materials.
Scarab's Clean Genome® platform is uniquely positioned to improve plasmid DNA and recombinant protein manufacturing yields and quality, offering a compelling value proposition to developers.
Exclusive licensing deals, like the one with Bionova, can provide significant non-dilutive funding and accelerate market penetration.

Risk Factors

The company faces competition from established reagent suppliers and alternative expression systems.
Adoption of new production hosts by biopharma can be slow due to regulatory and process changeover costs.
Revenue may be somewhat concentrated in carrier protein sales and the success of a limited number of key partnerships, creating dependency risks.

Competitive Landscape

Scarab competes in the microbial expression system market with large life science tools companies (e.g., Thermo Fisher, Agilent, Merck KGaA) and specialized synthetic biology firms. In the carrier protein space, it competes with other biomanufacturers and CDMOs that produce CRM197. Its key differentiation is the foundational science of its reduced-genome E. coli, which offers documented advantages in genetic stability, a critical factor for complex DNA and protein production.

More companies in Biologics / Biosimilars →More companies in United States →